首页> 美国卫生研究院文献>other >Structure of a Dihydroxycoumarin Active-Site Inhibitor in Complex with the RNase H Domain of HIV-1 Reverse Transcriptase and Structure-Activity Analysis of Inhibitor Analogs
【2h】

Structure of a Dihydroxycoumarin Active-Site Inhibitor in Complex with the RNase H Domain of HIV-1 Reverse Transcriptase and Structure-Activity Analysis of Inhibitor Analogs

机译:二羟基香豆素活性部位抑制剂与HIV-1逆转录酶RNase H结构域复合的结构和抑制剂类似物的结构活性分析

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

HIV encodes four essential enzymes: protease, integrase, reverse transcriptase (RT) associated DNA polymerase, and RT-associated ribonuclease H (RNase H). Current clinically approved anti-AIDS drugs target all HIV enzymatic activities except RNase H, which has proven to be a very difficult target for HIV drug discovery. Our high-throughput screening activities identified the dihydroxycoumarin compound F3284-8495 as a specific inhibitor of RT RNase H, with low micromolar potency in vitro. Optimization of inhibitory potency can be facilitated by structural information about inhibitor-target binding. Here, we report the crystal structure of F3284-8495 bound to the active site of an isolated RNase H domain of HIV-1 RT at a resolution limit of 1.71 Å. From predictions based on this structure, compounds were obtained that showed improved inhibitory activity. Computational analysis suggested structural alterations that could provide additional interactions with RT and thus improve inhibitory potency. These studies established proof-of-concept that F3284-8495 could be used as a favorable chemical scaffold for development of HIV RNase H inhibitors.
机译:HIV编码四种必需的酶:蛋白酶,整合酶,逆转录酶(RT)相关的DNA聚合酶和RT相关的核糖核酸酶H(RNase H)。当前临床上批准的抗艾滋病药物靶向除RNase H之外的所有HIV酶促活性,RNase H已被证明是发现HIV药物非常困难的靶标。我们的高通量筛选活动确定了二羟基香豆素化合物F3284-8495是RT RNase H的特异性抑制剂,体外微摩尔浓度低。关于抑制剂-靶标结合的结构信息可以促进抑制效能的优化。在这里,我们报告F3284-8495的晶体结构绑定到HIV-1 RT的分离的RNase H域的活性位点,分辨率极限为1.71Å。从基于该结构的预测,获得显示出改善的抑制活性的化合物。计算分析表明结构改变可以提供与RT的其他相互作用,从而提高抑制效能。这些研究建立了概念证明,即F3284-8495可用作开发HIV RNase H抑制剂的有利化学支架。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号